Brokerage Reports
Regeneron Pharmaceuticals, Inc. [REGN]
Reports for Purchase
Showing records 461 - 480 ( 593 total )
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Dupilumab''s Profile Broadens with Positive Phase IIa in Sinusitis
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Price: 10.00
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Price: 10.00
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Alirocumab''s Successful ODYSSEY Continues; Target Upped to $422
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Price: 25.00
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Price: 10.00
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Eylea Keeps Gaining Ground; Receives E.U. DME Approval
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Price: 10.00
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Price: 10.00
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q14 Results, Eylea Growth & Advanced Antibody Pipeline
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Price: 25.00
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Price: 25.00
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Priority Review Voucher Purchased for Alirocumab; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Price: 10.00
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
That''s A Lot of Positive Phase III''s; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Price: 10.00
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Price: 10.00
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Another Win for Eylea; Approved for DME in the U.S.; Target Upped to $399
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Price: 25.00
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MIDDAY SUMMARY
Provider: Roth Capital Partners, Inc.
Price: 10.00
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Eylea Sustains Vision Improvement in DME for 2 Years; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Price: 10.00
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Price: 10.00
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Positive Phase IIb Data In Atopic Dermatitis Bolsters Dupilumab Position
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Price: 25.00
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Price: 10.00
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Price: 10.00